TRANSDERMAL DELIVERY OF TETRAHYDRO-CANNABINOL

屈大麻酚在厌食症中作为止吐药是有效的，在癌症化疗中用于治疗恶心和频繁呕吐。目前是口服，并不总是有效。一项荟萃分析研究显示，在750个疗程的口服治疗中，约65%的患者对大麻酚反应不佳或部分反应。因此，高剂量的单次用药会引起镇静、精神错乱和焦虑等副作用。这些问题可以通过经皮贴片给予持续低剂量的屈大麻酚来最小化。这种给药方式可以减少与口服给药相关的吸收和代谢变化，另一方面可以避免肝脏首过失活，从而提高生物利用度和疗效。从体外扩散实验和不混溶溶剂之间的药物分布来估计治疗药物的血浆水平。在第一期SBIR项目中，承包商建议开发大麻酚皮肤黏附贴片，以更安全地将药物输送到系统中。

Dronabinol is effective as an anti-emetic in anorexia, and for treating nausea and frequent vomiting in cancer chemotherapy. This is currently administered orally, and is not always effective. A meta-analysis study revealed a poor or partial response to dronabinol in approximately 65% of 750 courses of oral therapy. Thus high single doses of this drug are administered causing side effects such as sedation, confusion, and anxiety. These problems could be minimized by the administration of sustained low doses of dronabinol via a trans-dermal patch. This route of administration will reduce the variation in absorption and metabolism, associated with oral administration and on the other hand increase the bio-availability and the efficacy by avoiding liver first-pass inactivation. Therapeutics plasma levels of dronabinol will be estimated from in vitro diffusion experiments and drug distribution between immiscible solvents. During this phase I SBIR project, the contractor proposes to develop the dronabinol dermal adhesive patch for safer delivery of drug to the system.